Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: A meta-analysis

Digestive Diseases and Sciences

Volumn 54, Issue 4, 2009, Pages 712-721

  Rahimi, Roja ^a   Nikfar, Shekoufeh ^b   Rezaie, Ali ^c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Balsalazide; Mesalazine; Meta analysis; Relapse; Remission; Tolerance

Indexed keywords

BALSALAZIDE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLHYDRAZINE DERIVATIVE;

ABDOMINAL PAIN; ALOPECIA; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; COCHRANE LIBRARY; COLON POLYP; CONFIDENCE INTERVAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ERYTHEMA NODOSUM; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INTESTINE MOTILITY; LETHARGY; MAINTENANCE THERAPY; MALAISE; MEDLINE; META ANALYSIS; NAIL DISEASE; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; RASH; RECTUM HEMORRHAGE; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCAPHOID FRACTURE; SCORING SYSTEM; SIDE EFFECT; SIGMOIDOSCOPY; SPIGELIAN HERNIA; SYSTEMATIC REVIEW; TENESMUS; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; COMPARATIVE STUDY; FEMALE; MALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; PHENYLHYDRAZINES; REMISSION INDUCTION;

EID: 63249130360     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0428-2     Document Type: Review

References (26)

1. EH Shen KM Das 2004 Current therapeutic recommendations: infliximab for ulcerative colitis J Clin Gastroenterol 38 741 745
2. T Kucharzik C Maaser A Lügering M Kagnoff L Mayer S Targan 2006 Recent understanding of IBD pathogenesis: implications for future therapies Inflamm Bowel Dis 12 1068 1083
3. A Rezaie S Khalaj M Shabihkhani S Nikfar MJ Zamani A Mohammadirad 2007 Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients Ann N Y Acad Sci 1095 305 314
4. R Rahimi S Nikfar A Abdollahi 2007 Meta analysis technique confirms the effectiveness of anti-TNFa in the management of active ulcerative colitis when administered in combination with corticosteroids Med Sci Monit 13 PI13 PI18
5. R Rahimi S Nikfar M Abdollahi 2007 Do anti tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A meta-analysis of controlled clinical trials Biomed Pharmacother 61 75 80
6. A Rezaie RD Parker M Abdollahi 2007 Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52 2015 2021
7. R Rahimi S Nikfar A Rezaie M Abdollahi 2007 A meta-analysis of antibiotic therapy for active ulcerative colitis Dig Dis Sci 52 2920 2925
8. G Jahanshahi V Motavasel A Rezaie AA Hashtroudi NE Daryani M Abdollahi 2004 Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases Dig Dis Sci 49 1752 1757
9. SB Hanauer 2008 Review article: evolving concepts in treatment and disease modification in ulcerative colitis Aliment Pharmacol Ther 27 S15 S21
10. F Dallegri L Ottonello A Ballestrero F Bogliolo F Ferrando F Patrone 1990 Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis Gut 31 184 186
11. AM Miles MB Grisham 1995 Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis Adv Exp Med Biol 371B 1317 1321
12. SP Travis DP Jewell 1994 Salicylates for ulcerative colitis-their mode of action Pharmacol Ther 63 135 161
13. P Desreumaux S Ghosh 2006 Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence Aliment Pharmacol Ther 241 S2 S9
14. RB Muijsers KL Goa 2002 Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis Drugs 62 1689 1705
15. A Tursi G Brandimarte GM Giorgetti G Forti ME Modeo A Gigliobianco 2004 Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis Med Sci Monit 10 PI126 PI131
16. DS Levine DS Riff R Pruitt L Wruble G Koval D Sales 2002 A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis Am J Gastroenterol 97 1398 1407
17. R Pruitt J Hanson M Safdi L Wruble R Hardi J Johanson 2002 Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis Am J Gastroenterol 97 3078 3086
18. W Kruis S Schreiber D Theuer JW Brandes E Schütz S Howaldt 2001 Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses Gut 49 783 789
19. JR Green AJ Lobo CD Holdsworth RJ Leicester JA Gibson GD Kerr 1998 Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group Gastroenterology 114 15 22
20. JR Green JA Gibson GD Kerr ET Swarbrick AJ Lobo CD Holdsworth 1998 Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group Aliment Pharmacol Ther 12 1207 1216
21. Jadad A (1998) Randomised controlled trials. BMJ Books, London
22. WJ Sandborn SB Hanauer 2003 Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis Aliment Pharmacol Ther 17 29 42
23. K Ragunath JG Williams 2001 Review article: balsalazide therapy in ulcerative colitis Aliment Pharmacol Ther 15 1549 1554
24. PB [tmp] McIntyre CA Rodrigues JE Lennard-Jones IG Barrison JG Walker JH Baron 1988 Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Aliment Pharmacol Ther 2 237 243
25. JR Green JC Manfield JA Gibson GD Kerr PC Thornton 2002 A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis Aliment Pharmacol Ther 16 61 68
26. JC Manfield MH Giaffer PA Cann D [tmp] McKenna PC Thornton CD Holdsworth 2002 A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis Aliment Pharmacol Ther 16 69 77